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DOI 10.1016/j.ccr.2010.10.002SUMMARYOncogene addiction is thought to occur cell autonomously. Immune effectors are implicated in the initiation
and restraint of tumorigenesis, but their role in oncogene inactivation-mediated tumor regression is unclear.
Here, we show that an intact immune system, specifically CD4+ T cells, is required for the induction of cellular
senescence, shutdown of angiogenesis, and chemokine expression resulting in sustained tumor regression
upon inactivation of the MYC or BCR-ABL oncogenes in mouse models of T cell acute lymphoblastic
lymphoma and pro-B cell leukemia, respectively. Moreover, immune effectors knocked out for thrombospon-
dins failed to induce sustained tumor regression. Hence, CD4+ T cells are required for the remodeling of the
tumor microenvironment through the expression of chemokines, such as thrombospondins, in order to elicit
oncogene addiction.INTRODUCTION
The inactivation of a single oncogene is sufficient to induce sus-
tained tumor regression in vivo through the phenomenon of
oncogene addiction, as has been demonstrated experimentally
in many conditional transgenic mouse model systems (Felsher,
2008; Sharma and Settleman, 2007; Weinstein and Joe, 2008)
and through the development of targeted therapeutics such as
Gleevec (Weinstein and Joe, 2006). Oncogene addiction is asso-
ciated with proliferative arrest, apoptosis, differentiation, and
cellular senescence as well as the shutdown of host programs
such as angiogenesis (Felsher, 2003; Felsher and Bishop,Significance
Through transgenic mouse models of conditional oncogene i
system results in a 10- to 1000-fold reduction in the rate, exte
vation. We uncovered an unanticipated role for CD4+ T cell ef
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strategies to identify therapeutic agents utilize in vitro model
immune system. Our results argue for the necessity of models
uate the potential efficacy of targeted therapeutics for maxim
Can1999; Giuriato et al., 2006; Jain et al., 2002; Shachaf et al.,
2004; Wu et al., 2007). To date, it has been presumed that onco-
gene inactivation induces tumor regression through cell autono-
mous mechanisms, independent of host effector cells.
The host immune system plays an important role in tumorigen-
esis. Both antigen-dependent and -independent mechanisms
are implicated through multiple cellular effectors and effects on
inflammation and the tumor microenvironment (Crowe et al.,
2002; Shankaran et al., 2001). Indeed, it is well documented
that CD8+ T cells contribute to antigen-dependent and NK cell-
mediated tumor elimination (Shanker et al., 2007; van der Brug-
gen et al., 1991). Additionally, CD4+ T cellsmay also contribute tonactivation, we show that the absence of an intact immune
nt, and duration of tumor regression upon oncogene inacti-
fectors in mediating cellular senescence and the shutdown
xpression of thrombospondin-1 in immune effectors. Most
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Role of Immune System in Oncogene Addictiontumor regression (Corthay et al., 2005; Qin and Blankenstein,
2000). Chemokines produced by the immune system have
been shown to play an important role during tumor evolution
and therapeutic response (Rossi and Zlotnik, 2000; Smyth
et al., 2004).
In general, tumors coevolve with host immune effectors and
chemokines through a process that has been described as
immune editing (Dougan and Dranoff, 2009; Dunn et al., 2002;
Dunn et al., 2006; Reiman et al., 2007; Swann et al., 2008).
Immune editing has been dramatically illustrated in several
models of carcinogenesis (Bui et al., 2006; Shankaran et al.,
2001; Willimsky and Blankenstein, 2005). Host immune effectors
also contribute to the initiation of tumorigenesis through pro-
found effects on the tumor microenvironment (Coussens and
Werb, 2002; de Visser et al., 2006). Thus, the immune system
appears to play a complex role in both the initiation and restraint
of tumorigenesis.
The role of the immune system in mediating tumor regression
upon targeted oncogene inactivation is not known. Hosts that
are immune compromised have a markedly increased incidence
of many different types of cancers (Birkeland et al., 1995; Dunn
et al., 2002; Pham et al., 1995). The host immune system is inti-
mately involved not only in the promotion and prevention of
neoplasia but also in determining the therapeutic response to
treatment of cancer (Andreu et al., 2010; Boshoff and Weiss,
2002; Dave et al., 2004; Galon et al., 2006; Gatti and Good,
1971; Kohrt et al., 2005; Zitvogel et al., 2008). However, experi-
mental study of therapeutics for cancer is usually performed
in vitro or in vivo in immune compromised hosts, circumstances
in which immune effectors are necessarily absent. Thesemodels
do not account for the role of host-tumor interactions and the
role of the immune system.
The MYC oncogene has been implicated in the pathogenesis
of many human tumors (Meyer and Penn, 2008).MYC is involved
in the etiology of many types of lymphoma including Burkitt’s
large cell and T cell acute lymphoblastic lymphoma (T-ALL)
(Boxer and Dang, 2001; Pelengaris et al., 2002). We have
previously described our conditional transgenic mouse models
of MYC-induced T cell acute lymphoblastic lymphoma (T-ALL)
(Felsher and Bishop, 1999). The inactivation ofMYC is sufficient
to induce sustained tumor regression associated with prolifera-
tive arrest, apoptosis, differentiation, cellular senescence and
the shutdown of angiogenesis (Felsher and Bishop, 1999; Giur-
iato et al., 2006; Wu et al., 2007). Here, we show that defects in
the host immune system have a profound influence on the ability
of oncogene inactivation to elicit oncogene addiction.RESULTS
Immune System Is Required for Rapid, Complete,
and Sustained Tumor Regression
To interrogate if the immune system is required to elicit onco-
gene addiction upon MYC inactivation, we transplanted lucif-
erase labeled tumors from our conditional transgenic mouse
model of MYC-induced hematopoietic tumorigenesis into wild-
type hosts and in hosts with specific defects in immune com-
partments: SCID, RAG2/cgc/, RAG2/, CD4/CD8/,
CD4/CD8+/+, CD4+/+CD8/ (Figures 1A and 1B). By using486 Cancer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Incbioluminescence imaging, we could measure the kinetics of
tumor regression upon MYC inactivation.
Tumors initially exhibited regression regardless of the host
immune status (Figures 1A, 1B, and 1C). However, severely
immune compromised hosts (SCID and RAG2/cgc/ mice
deficient in the adaptive immune system and NK cells) demon-
strated significantly delayed kinetics of tumor regression upon
MYC inactivation compared with wild-type (WT) hosts (Fig-
ure 1D, SCID versus WT, p < 0.001) and failed to execute
complete tumor elimination with up to 1000-fold more minimal
residual disease (MRD) after MYC inactivation (Figure 1E,
SCID versus WT, p < 0.0001; RAG2/ cgc/ versus WT, p =
0.01 at the nadir of luciferase activity upon MYC inactivation).
Similarly, less severely immune compromised hosts also ex-
hibited delayed kinetics (Figures 1B and 1D, RAG2/ versus
WT, p = 0.02; CD4/CD8/ versus WT, p = 0.02) and a signif-
icantly increased MRD (Figure 1E, RAG2/ versus WT, p =
0.01; CD4/CD8/ versus WT, p < 0.01). Hence, an intact
immune system is required for rapid and complete tumor
regression.
To determine if host immune status influenced the frequency
of tumor recurrence, we continued to observe mice for 80 days
after MYC inactivation noting that tumors recurred at a statisti-
cally significant higher frequency in SCID, RAG2/cgc/,
RAG2/, and CD4/CD8/ hosts (87.5%, 100%, 100%, and
80%, respectively) compared withWT hosts (9%) (immune com-
promised hosts versus WT, p < 0.0001, also see Figure 1F).
CD4/ but not CD8/ deficient hosts exhibited a significant
influence on tumor recurrence (28.5%, 0%, respectively) (Fig-
ure 1F). Correspondingly, CD4+, but not CD8+ T cell deficiency
alone was sufficient to impede sustained tumor regression com-
pared to WT mice (Figure 1F, WT versus CD4/, p = 0.02).
Similar results could be obtained using nonluciferase labeled
tumors (Figure S1A). By qPCR analysis it was confirmed that
doxycycline treatment resulted in similar suppression of trans-
genic MYC expression regardless of host immune status (Fig-
ure S1B). Hence, defects in the host immune system prevented
sustained tumor regression upon MYC inactivation.
Immune System Is Not Required to Induce Proliferative
Arrest or Apoptosis
Previously, we have shown that uponMYC inactivation in a trans-
genic model of T-ALL, tumor cells undergo proliferative arrest
and apoptosis (Felsher and Bishop, 1999). We determined if
the mechanism by which immune cells were contributing to the
process of tumor regression was through effects on proliferation
and apoptosis of tumor cells before and after MYC inactivation
(Figures 2A and 2B). After 4 days of MYC inactivation, tumors
from wild-type and immunodeficient hosts exhibited an overall
loss of pleomorphic characteristics evidenced by a similarly
marked reduction in cell size and nuclear to cytoplasmic ratio
in both cohorts. Importantly, upon MYC inactivation, we
observed marked changes in the total number of cells per field
and carefully controlled for these changes in our quantification
of TUNEL and Ki67 staining.
To measure apoptosis, TUNEL staining was performed.
Apoptosis occurred similarly upon MYC inactivation regardless
of host immune status (Figure 2A), suggesting that initial tumor
regression occurs similarly regardless of the presence or.
Figure 1. An Intact Immune System Is
Required for Sustained Tumor Regression
(A and B) Graphical representation of tumor
regression and relapse kinetics as measured
by bioluminescence imaging. Luciferase-labeled
tumor cell lines from our conditional mouse
T-ALL model were injected s.c. into different
cohorts of mice (WT, n = 11; CD8/, n = 7;
CD4/, n = 6; CD4/CD8/, n = 5; SCID, n = 8;
RAG2/, n = 7; RAG2/cgc/, n = 3).MYC was
inactivated by administering doxycycline (dox) to
the mice when tumors reached a comparable
bioluminescence signal (108p/s/sr/cm2).
(C) Bioluminescence images of tumors regressing
in the different immunodeficient hosts. Data are
representative of three experiments.
(D) Quantitative analysis of tumor regression in the
indicated hosts, 8 days after MYC inactivation.
(E) Quantification of minimum residual disease
in the indicated hosts. Data are presented as
the minimum bioluminescence signal after MYC
inactivation.
(F) Kaplan Meier curves of tumor-free survival in
the various immunodeficient genotypes. A mouse
was scored as a relapse when its tumor biolumi-
nescence signal first began to increase after tumor
regression. The log-rank test was used to com-
pare survival curves. Data are representative of
three experiments using two cell lines and one
primary tumor. Statistical significance was
analyzed by pooling data from all experiments
(WT, n = 43; CD8/, n = 20; CD4/, n = 24;
CD4/CD8/, n = 15; SCID, n = 15; RAG2/,
n = 46) (p value evaluated by unpaired Student’s
t test) is shown.
*p < 0.01, **p < 0.001, ***p < 0.0001. Error bars are
± SEM. See also Figure S1.
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Role of Immune System in Oncogene Addictionabsence of an immune system. Quantification of TUNEL staining
revealed a 2-fold increase in the extent of apoptosis upon MYC
inactivation in tumors from WT hosts (Figure 2B, WT MYC On
versus Off, p = 0.05). Moreover, the apoptosis in regressing
tumors from WT hosts was not significantly different from that
of regressing tumors in either RAG2/ or CD4/ hosts (Fig-
ure 2B, WT versus RAG2/, CD4/ MYC Off, p = 0.3 and 0.3,
respectively). Finally there was a small but statistically insignifi-
cant increase in the levels of apoptosis upon MYC inactivation
in RAG2/ or CD4/ hosts (Figure 2B, RAG2/, CD4/
MYC On versus Off, p = 0.07 and 0.09, respectively). Hence,
the absence of the immune system may slightly impede
apoptosis of tumor cells upon MYC inactivation.
Next, changes in cellular proliferation upon MYC inactivation
were measured by Ki67 staining. MYC inactivation in tumors
from WT and immunodeficient hosts resulted in a significant
reduction in Ki67 staining (Figures 2A and 2B, WT, RAG2/,
CD4/ MYC On versus MYC Off, p < 0.01). Interestingly, in
comparison toWT hosts, RAG2/ but not CD4/ hosts, under-
went a statistically significant further decrease in Ki67 staining
upon MYC inactivation (WT versus RAG2/ or CD4/ MYCCanOff, p = 0.02 or p < 0.05, respectively). Thus, the absence of
the host immune system either has no effect or modestly
enhances the effect of MYC inactivation in inducing proliferative
arrest.
Immune System Is Required to Induce Cellular
Senescence and the Shutdown of Angiogenesis
We have reported that upon MYC inactivation tumor cells
undergo cellular senescence (Wu et al., 2007) and the shutdown
of angiogenesis (Giuriato et al., 2006). We examined the role
of both processes. Tumors from WT hosts expressed a 20-fold
increase in senescence-associated acidic b-gal (SA-b-Gal)
activity upon MYC inactivation and demonstrated a 26- and
6-fold increase in senescence-associated markers, p16INK4a
and p21, respectively, upon MYC inactivation (Figures 3A and
3B). In contrast, MYC inactivation in tumors in RAG2/ and
CD4/ mice did not result in increased SA-b-Gal or the induc-
tion of p16INK4a or p21 (Figures 3A and 3B, WT versus
RAG2/ MYC Off SA-b-Gal, p = 0.01, p16 staining p = 0.002,
p21 staining p = 0.01; WT versus CD4/, MYC Off SA- b-Gal,
p = 0.009, p16 staining, p = 0.0005, p21 staining, p = 0.004).cer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Inc. 487
Figure 2. The Immune System Does Not Influence Apoptosis or Proliferative Arrest upon MYC Inactivation
(A) Micrographs of hematoxylin and eosin staining (left panel), TUNEL (middle panel), and Ki67 (right panel) immunostaining of tumors derived from untreated
(MYC On) and 4 day dox-treated mice (MYC Off) from WT (top panel), RAG2/ (middle panel), and CD4/ (bottom panel) hosts. Scale bar = 100 mm.
(B) Quantitative representation of Ki67 (top panel) and TUNEL (bottom panel) immunostaining shown in (A) for 0, 2, and 4 days after MYC inactivation. Quanti-
fication of TUNEL and Ki67 immunostaining is presented as the average percentage of TUNEL-positive cells and area of Ki67-positive regions, respectively,
within the tumors. At least five different fields from three different tumors injected with at least two different tumor cell lines for each different condition. Statistical
significance (p value evaluated by unpaired Student’s t test) is shown. *p < 0.01, **p < 0.001, ***p < 0.0001. Error bars are represented as ± SEM.
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Role of Immune System in Oncogene AddictionThus, in immune deficient mice, MYC inactivation is impeded
from inducing cellular senescence in tumor cells. Notably,
CD4+ T cells specifically appeared to be required.
We determined if an intact immune system was required for
MYC inactivation to induce the shutdown of angiogenesis asso-
ciated with the secretion of TSP-1, a potent antiangiogenic
protein (Giuriato et al., 2006; Kazerounian et al., 2008; Lawler,
2000). Upon MYC inactivation there was a 3.5-fold induction of
TSP-1 in tumors from WT hosts but not in RAG2/ or CD4/
hosts (Figure 4A, WT versus RAG2/, CD4/ MYC Off, p =
0.001). Furthermore, while tumors in WT mice demonstrated
very little change in mean vascular density (MVD) as measured
by CD31 staining upon MYC inactivation (Figure 4B), RAG2/
and CD4/ mice exhibited a 5- and 12-fold, respectively,
increase in tumor MVD upon MYC inactivation (Figures 4A and488 Cancer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Inc4B, RAG2/ MYC On versus Off, p < 0.0001; CD4/ MYC On
versus Off, p = 0.07). Thus, the absence of CD4+ T cells impairs
the ability of MYC inactivation to induce cellular senescence as
well as shutdown angiogenesis.
Finally, TSP-1 expression requires host immune cells and
specifically CD4+ T cells. Indeed, we found that TSP-1 protein
expression is markedly decreased in spleens of immune com-
promised versus wild-type hosts (Figure S2A). Further, we
show that activated CD4+ T cells express TSP-1 (Figure S2B).
CD4+ T Cells Home to the Tumor and Are Sufficient
to Restore Sustained Tumor Regression
We examined if CD4+ T cells were homing to the tumor site upon
oncogene inactivation. Upon adoptive transfer into RAG2/
hosts, luciferase+ CD4+ T cells rapidly localized to the tumor.
Figure 3. An Intact Immune System Is Required for the Induction of Cellular Senescence upon MYC Inactivation
(A) Micrographs of senescence associated b-galactosidease (SA b-gal, left panel), p16 (middle panel), and p21 (right panel) immunostaining of tumors derived
from untreated (MYC On) and 4 day dox-treated (MYC Off) mice of the indicated genotypes. Scale bar = 100 mm.
(B) Quantification of SA-b-gal (top panel), p16 (middle panel), and p21 (bottom panel) staining shown in (A) for 0, 2, and 4 days after MYC inactivation. Quanti-
fication is presented as the average percentage of positively stained regions within the tumors. At least five different fields from three different tumors injectedwith
at least two different tumor cell lines were analyzed for each different condition. Statistical significance (p value evaluated by unpaired Student’s t test) is shown.
*p < 0.01, **p < 0.001, ***p < 0.0001. Error bars are ± SEM.
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of these tumors before and after MYC inactivation (Figure 5A).
Inactivating this oncogene causes CD4+ T cells to localize at
the tumor site as early as 4 days after oncogene inactivation,
peak at day 12 and persist up to 3 weeks afterMYC inactivation.
Thus, MYC inactivation is associated with trafficking of CD4+
T cells to sites of tumor involvement. Notably, CD4+ T cell-
depleted luciferase+ splenocytes also localized to the site of
the tumor upon MYC inactivation, suggesting the recruitment
of additional host immune effector populations (Figure S3A).
Next, we evaluated if we could restore the ability of MYC
inactivation to induce sustained tumor regression in immune
compromised hosts by adoptively transferring specific lympho-Cancyte populations into RAG2/mice. By FACS analysis, we con-
firmed reconstitution of effector cells (Figure S3B). As expected,
RAG2/ mice adoptively transferred with splenic lymphocytes
exhibited sustained regression (Figure 6B). RAG2/ hosts dem-
onstrated a significant amount of MRD after MYC inactivation
compared with WT hosts (Figures 5B and 5C, RAG2/ versus
WT, p = 0.007). Reconstitution of immunodeficient hosts with
naive CD8+ T cells continued to have a significant burden of
MRD (Figure 5C, RAG2/CD8+ versus WT, p = 0.03), whereas
reconstitution of RAG2/ hosts with naive CD4+ T cells
completely eliminatedMRD, similar toWT hosts uponMYC inac-
tivation (Figure 5C, RAG2/CD4+ versus WT, p = 0.09). More-
over, RAG2/ hosts adoptively transferred with CD4+ T cellscer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Inc. 489
Figure 4. An Intact Immune System Is Required for the Inhibition of Angiogenesis upon MYC Inactivation
(A) Micrographs of TSP-1 (left panel) and CD31 (right panel) immunohistochemical and immunofluorescence staining of tumors derived from untreated (MYCOn)
and 4 day dox-treated (MYC Off) mice of the indicated genotypes. Scale bar = 100 mm.
(B) Quantification of TSP-1 (top panel) and CD31 (bottom panel) staining shown in (A). Quantification is presented as the average percentage of positively stained
regions within the tumors. At least five different fields from two different tumors were analyzed for each different condition. Statistical significance (p value eval-
uated by unpaired Student’s t test) is shown. *p < 0.01, **p < 0.001, ***p < 0.0001. Error bars are ± SEM.
See also Figure S2.
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compared with RAG2/ or RAG2/ hosts reconstituted with
CD8+ T cells (Figures 5B and 5D, RAG2/ versus RAG2/
CD4+, p = 0.007, RAG2/CD4+ versus RAG2/CD8+, p =
0.03). Hence, restoration of CD4+ T cells alone was sufficient
for the ability of MYC inactivation to eliminate MRD and induce
sustained tumor regression.
Host Immune System Is Required to Elicit Changes
in Chemokine Expression
We measured relative fold changes in cytokine production in
tumors growing in WT or RAG2/ hosts after MYC inactivation
(Figure 6A). MYC inactivation in tumors from WT compared490 Cancer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Incwith RAG2/ hosts revealed an upregulation of antiproliferative
and antiangiogenic (‘‘antitumor’’) cytokines that suggest poten-
tial involvement by other immune effectors. Eotaxin-1 and IL-5
(Figure 6A, WT versus RAG2/ fold change uponMYC inactiva-
tion p = 0.02 and p = 0.003, respectively) are potent TH2 cyto-
kines that have been implicated in the recruitment of an eosino-
phil-mediated antitumor inflammatory response (Simson et al.,
2007). IFN-g was observed to increase over 4-fold upon MYC
inactivation in the WT hosts with virtually no change in the
absence of the host immune system (WT versus RAG2/ fold
change uponMYC inactivation p = 0.03) while TNF-a was signif-
icantly downregulated in RAG2/ hosts (RAG2/ MYC On
versus Off, p = 0.02); its upregulation was close to statistical.
Figure 5. CD4+ T Cells Home to the Tumor and Are Sufficient to Induce Sustained Tumor Regression upon MYC Inactivation
(A) Bioluminescence signal of luciferase+CD4+ T cells that home to the tumor microenvironment. RAG2/mice were reconstituted with luciferase+ CD4+ T cells
and unlabeled tumor cell lines were injected s.c. 8 days post reconstitution.MYCwas inactivated when tumors grew to a size of 1000 mm3. Data are represented
as bioluminescence signal (average radiance) plotted against time after MYC inactivation (n = 3).
(B) Tumor regression and relapse kinetics measured by bioluminescence imaging. RAG2/mice were reconstituted with CD4+ (RAG2/reconst.CD4+T cells,
n = 5) or CD8+ (RAG2/reconst. CD8+T cells, n = 6) T cells fromWTmice. Eight days after reconstitution, luciferase+ tumor cell lines were injected s.c.MYCwas
inactivated when tumors in all hosts reached a comparable bioluminescence signal. Data are presented as bioluminescence signal (average radiance) plotted
against time after MYC inactivation. WT (n = 3) and RAG2/ (n = 3) mice were used as positive and negative controls.
(C) Quantification of minimum residual disease. Bioluminescence signals of tumors at their maximally regressed state are plotted against genotype. Statistical
significance (p value evaluated by unpaired Student’s t test) is shown. *p < 0.01, **p < 0.001, ***p < 0.0001. Error bars are ± SEM.
(D) Kaplan Meier curves of tumor-free survival in the reconstituted RAG2/, RAG2/, and WT mice. Log-rank test was used compare the survival curves.
Data are representative of three experiments. Statistics were performed including all data: n = 14, RAG reconstituted with CD8+ T cells: n = 12. reconst. =
reconstituted with.
See also Figure S3.
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Both cytokines have been shown by many to be critical media-
tors of potent CD4+ antitumor activity (Qin and Blankenstein,
2000; Thomas and Hersey, 1998). Interestingly, MCP-1, a potent
chemoattractant of inflammatory tumor-associated macro-
phages (TAMs), specifically, tumor-promoting M2 macrophages
(Allavena et al., 2008; Hu et al., 2009), was significantly downre-
gulated in the tumors from immunodeficient hosts compared
with WT (WT versus RAG2/ fold change upon MYC inactiva-
tion p = 0.008).
Also, the downregulation of ‘‘protumor’’ cytokines was mea-
sured in tumors fromWT and RAG2/ hosts. Vascular endothe-Canlial growth factor (VEGF) was downregulated almost 4-fold in WT
hosts (WT MYC On versus Off, p = 0.01), whereas no change in
its expression could be detected in tumors from immunodefi-
cient hosts. IL-b decreased significantly close to 2-fold (WT
versus RAG2/ fold change upon MYC inactivation, p = 0.02);
downregulation of these two cytokines suggests enhanced
suppression of angiogenesis in the presence of an intact host
immune system upon MYC inactivation (Kowanetz and Ferrara,
2006; Shchors et al., 2006).
Finally, RAG2/ hosts that had been reconstituted with CD4+
T cells exhibited similar changes in chemokine expression to WT
hosts upon MYC inactivation (Figure S4B). The antitumorcer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Inc. 491
Figure 6. Cytokines Produced by the
Immune System Contribute to Sustained
Tumor Regression upon MYC Inactivation
(A) Graphical representation of fold change of indi-
cated cytokines upon MYC inactivation in tumors
from WT and RAG2/ hosts. Tumors from WT
and RAG2/mice were harvested at tumor onset
and 4 days afterMYC inactivation and run on a lu-
minex platform to check for protein expression
of 21 different cytokines. The significant fold
changes in the various cytokines upon MYC inac-
tivation were log2 transformed and plotted for
various pro- and antitumor cytokines. *p < 0.01,
**p < 0.001. Asterisks above the bars represent
significance in cytokine expression upon MYC
inactivation in the indicated host. Error bars
are ± SEM.
(B) Kaplan-Meier curves of tumor-free survival of
reconstituted RAG2/, RAG2/, and WT mice.
RAG2/ mice were reconstituted with spleno-
cytes from WT (n = 18) or TSP-1,2/ (n = 16)
mice i.v. Eight days post reconstitution, mice
were transplanted with lymphoma cells s.c. MYC
was inactivated when tumors were 1000 mm3.
WT (n = 8) and RAG2/ (n = 11). Log-rank test
was used to analyze survival of indicated geno-
types. Data are representative three experiments.
(C) Kaplan-Meier curves of tumor-free survival of
RAG2/ mice injected with TSP-1 transfected
tumor cell lines (n = 5) or vector transfected control
tumor cell lines (n = 5). A p53/ conditional MYC
lymphoma cell line was used.
See also Figure S4.
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Role of Immune System in Oncogene Addictioncytokines (eotaxin, IFN-g and RANTES) increased, while the
protumor cytokine, VEGF decreased in protein expression
(Figure S4B). Thus, the host immune status is responsible for
the regulation of changes in cytokine expression.
TSP Expression Is Required for Sustained Tumor
Regression uponMYC Inactivation
Our results suggested to us the possibility that specific cyto-
kines may be critical to the remodeling of the tumor and the
tumor microenvironment upon MYC inactivation. We used two
approaches to investigate the role of TSP-1. First, we reconsti-
tuted RAG2/ mice with splenocytes from either TSP-1,2+/+
(WT) or TSP-1,2/ mice. Both TSP-1 and 2 have been impli-
cated in the inhibition of angiogenesis and have similar structural
domains (Kazerounian et al., 2008; Lawler, 2000). By FACS anal-
ysis, we verified equivalent immune reconstitution (Figure S4A).
Indeed, RAG2/ mice reconstituted with TSP-1,2/ spleno-
cytes completely failed to protect from sustained tumor regres-

















A.stituted with WT splenocytes (Figure 6B,
relapse rate WT versus TSP-1,2/,
10% versus 100%, p = 0.02). We con-
clude that TSP expression in immune
effectors is important for sustained tumor
regression upon MYC inactivation.
Next, we addressed whether we
could bypass the requirement for TSP-1xpression from host immune cells by artificially introducing
SP-1 into tumor cells. We compared tumor recurrence upon
YC inactivation in RAG2/ hosts of tumors infected with
vector control versus tumors infected with a TSP-1 expression
ector. TSP-1 overexpressing tumors exhibited a delay in the
inetics (mean latency 80 versus 102 days) and a decreased fre-
uency of tumor recurrence (40% versus 100%) resulting in a
tatistically significant survival advantage (Figure 6C, RAG2/
SP-1+ versus RAG2/, p = 0.02). Thus, TSP-1 overexpression
f tumor cells is sufficient to increase the duration and frequency
f sustained tumor regression uponMYC inactivation in immune
ompromised hosts.
yclosporine A Treatment of Primary Tumors Impedes
enescence and Shutdown of Angiogenesis
o examine if similar results would be observed in primary trans-
enic tumors, we determined the influence of the pharmacolog-
al suppression of the host immune system with cyclosporine
(Shevach, 1985) on the consequences of MYC inactivation.
Figure 7. Cyclosporine A Treatment Inhibits Induction of Senescence and Inhibition of Angiogenesis in Tumors from PrimaryMYC-Induced
T-ALL
(A) Micrographs of hematoxylin and eosin, Ki67, SA-b-gal, p16, p21, CD31, and TSP-1 immunostaining (ordered from top to bottom) of tumors derived from
untreated and cyclosporine A-treated primary tumor bearing mice (MYC On and 4 day dox-treated MYC Off). Scale bar = 100 mm.
(B) Quantification of immunostaining shown in (A). Ordered from left to right, the graphs represent quantification of Ki67, SA-b-gal, p16, p21, CD31, and TSP-1
expression. Quantification is the average percentage of positively stained regions within the tumors. At least five different fields from two different tumors were
analyzed. Statistical significance (p value evaluated by unpaired Student’s t test) is shown. *p < 0.01, **p < 0.001, ***p < 0.0001. Error bars are ± SEM.
See also Figure S5.
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Role of Immune System in Oncogene AddictionCyclosporine A did not have any direct effects on the prolifera-
tion of tumor cells in vitro (Figure S5). Cyclosporine A treated
primary transgenic mice illustrated a marked inhibition on the
ability of MYC inactivation to induce both cellular senescence
as measured by staining for SA b-galactosidase (70% versus
1%; p < 0.01), p16 (6% versus 2%; p < 0.05), and p21 (0.5%
versus 0.1%, p < 0.01) as well as the suppression of angiogen-Canesis as measured by decrease in staining for CD31 (0.2% versus
0.4%, p = 0.05) and the induction of TSP-1 (6% versus 1%, p =
0.0006) (Figures 7A and 7B). Thus, cyclosporine A blocked the
ability of MYC inactivation to induce senescence and shut
down angiogenesis. We observed no effects on apoptosis as
measured by TUNEL staining (data not shown). However, cyclo-
sporine A treatment may suppress the ability ofMYC inactivationcer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Inc. 493
Figure 8. An Intact Immune System Is Required for Sustained Regression of Tumors in a Conditional Mouse Model of BCR-ABL-Induced
B-ALL
(A) Kaplan-Meier curves of tumor-free survival of RAG2/ (n = 9) and WT (n = 4) mice transplanted with unlabelled leukemia cells i.p. When mice were moribund
with tumor, BCR-ABL was inactivated, and mice were scored for relapse.
(B) Micrographs and quantification of Ki67, SA-b-gal, and TSP-1 immunostaining (ordered from top to bottom) of tumors derived from untreated (BCR-ABL On)
and doxycycline-treated (BCR-ABL Off) wild-type and immunodeficient tumor-bearing mice. Scale bar = 100 mm. Quantification is average percentage of
positively stained regions. At least five different fields from two different tumors were analyzed for each different condition. Statistical significance (p value eval-
uated by unpaired Student’s t test) is shown. *p < 0.01, **p < 0.001, ***p < 0.0001.
(C) Model for role of immune system in eliciting oncogene addiction.
See also Figure S6.
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Role of Immune System in Oncogene Addictionto induce proliferative arrest. Interestingly, cyclosporine A
seemed to inhibit proliferation during tumor progression when
MYC was still activated. This suggests, that when MYC is on,
T cells might promote tumor formation indicating the dual nature
of the immune response in cancer (de Visser et al., 2006).
Immune System Is Required for Sustained Regression
of BCR-ABL-Induced B Cell Acute Lymphocytic
Leukemia (B-ALL)
To determine if our results would generalize to another model of
hematopoietic tumorigenesis, we used a conditional transgenic
model of BCR-ABL-induced pro-B cell lymphocytic leukemia494 Cancer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Inc(B-ALL) (Huettner et al., 2000). First, we determined if host
immune status influenced the ability of BCR-ABL inactivation
to induce sustained tumor regression. Similar to MYC inactiva-
tion, tumors upon BCR-ABL inactivation underwent sustained
tumor regression in wild-type hosts while 100% of the immuno-
deficient hosts relapsed within 14 days of BCR-ABL inactivation
(Figure 8A, WT versus RAG2/, p = 0.006). Hence, BCR-ABL
inactivation also induces sustained tumor regression only in
immune intact hosts.
Upon BCR-ABL inactivation, Ki67 expression showed a non-
significant decrease in tumors transplanted into wild-type hosts
but no change in tumors transplanted into immunodeficient.
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Role of Immune System in Oncogene Addictionhosts. Ki67 expression was higher in tumors transplanted into
immunodeficient hosts compared with those transplanted into
immune intact hosts (Figure 8B, WT BCR-ABL off versus immu-
nodeficient BCR-ABL off p = 0.03). Cellular senescence
increased upon BCR-ABL inactivation in tumors from wild-type
hosts versus immunodeficient hosts as measured by increased
SA-b-gal staining (4% versus 0.4%, p = 0.05). Finally, there
was a 3-fold increase in TSP-1 upon BCR-ABL inactivation in
tumors from immunocompetent hosts while TSP-1 expression
did not change upon BCR-ABL inactivation in immunodeficient
hosts (Figure 8B, TSP-1 panel, WT BCR-ABL on versus BCR-
ABL off, p < 0.0001; WT BCR-ABL Off versus immunodeficient
BCR-ABL Off, p = 0.0001). We were unable to measure any
significant CD31 expression in any of the tumors. Hence, BCR-
ABL inactivation also induces sustained tumor regression only
in immune intact hosts.DISCUSSION
Oncogene addiction has been presumed to be a cell autono-
mous process. Here, we have shown that interactions between
the tumor microenvironment and the immune system are essen-
tial for sustained tumor regression upon oncogene inactivation.
In the absence of an intact immune system, we see a 10- to
1000-fold reduction in the rate, extent, and duration of tumor
regression upon MYC inactivation. The absence of CD4+
T cells alone was sufficient to markedly impede sustained tumor
regression. Thus, oncogene addiction is not necessarily cell
autonomous. CD4+ T cells may play a critical role in enabling
MYC inactivation to elicit changes in the microenvironment and
in cytokine expression that appear to be required for cellular
senescence and the shutdown of angiogenesis. TSP-1 must
be expressed by immune effectors to cooperate with MYC
inactivation to induce tumor regression. Our results generalized
to primary tumors from MYC-induced T-ALL bearing hosts that
had been treated with the immunosuppressive agent cyclo-
sporine A and a conditional transgenic model of BCR-ABL-
induced B-ALL. Oncogene inactivation generally may induce
tumor regression through immune cell-dependent mechanisms.
Our observations are consistent with a multitude of reports
that document the role of the immune system in neoplasia (de
Visser et al., 2005, 2006; Dunn et al., 2002; Soucek et al.,
2007). Tumors coevolve in the context of an intact immune
system through the process of immune editing, resulting in tumor
elimination, dormancy, or evolving to escape the immune system
and progress to full malignancy (Dunn et al., 2002; Guerra et al.,
2008; Teng et al., 2008). Upon MYC inactivation, a massive
recruitment of CD4+ T cells occurs that is associated with
marked changes in cytokine production in the tumor microenvi-
ronment leading to cellular senescence and the shutdown of
angiogenesis. TSP-1 is one of the critical chemokines. Interest-
ingly, immune effector recruitment and associated changes in
chemokines occur upon restoration of the tumor suppressor
p53 in both liver cancer (Xue et al., 2007) and upon MYC inacti-
vation in lymphoma (Giuriato et al., 2006).
Provocatively, CD4+ T cells emerged as the critical host
effector population for sustained tumor regression upon MYC
inactivation. Notably, hosts deficient in CD4+ T cells exhibitedCanimpaired kinetics, degree and durability of tumor regression as
well as reduced senescence and suppression of angiogenesis
upon MYC inactivation. The reconstitution of CD4+ T cells into
RAG2/ hosts alone was capable of restoring the ability of
MYC inactivation to induce sustained tumor regression. The
reconstitution of CD4+ T cells into RAG2/ hosts had more
potent effects on tumor regression compared with the depletion
of these cells, perhaps reflecting that in hosts that are congeni-
tally defective for a specific immune compartment there
may be compensation from other immune effectors (Xing et al.,
1998).
CD4+ T cells have been previously implicated in the restraint of
tumor growth through regulation of antigen dependent mecha-
nisms involving either macrophages or cytotoxic T cells (Corthay
et al., 2005; Dranoff et al., 1993; Qin and Blankenstein, 2000).
Intriguingly, host CD4+ T cells sculpted the tumor’s response
to MYC inactivation, likely not by their modest influence upon
apoptosis or proliferation, but by dramatically inducing cellular
senescence and the shutdown of angiogenesis, processes
previously suggested by us to be integral to the ability of MYC
inactivation to effect sustained tumor regression. Two of the hall-
marks of oncogene addiction, both the induction of cellular
senescence and the suppression of angiogenesis, have been
linked to the expression of cytokines known to be expressed
by CD4+ T cells (Acosta et al., 2008; Beatty and Paterson,
2001; Kuilman et al., 2008; Muller-Hermelink et al., 2008).
Thus, CD4+ T cells are one important component of the mech-
anism of tumor regression upon oncogene inactivation. Other
host immune effectors are likely to contribute, and we recognize
that other innate and adaptive immune compartments are also
likely to be involved includingmacrophages, NK cells, mast cells,
and B cells. Recent work suggests that mast cells and macro-
phages both may be critical (Soucek et al., 2007; Xue et al.,
2007). Indeed, it is possible that CD4+ T cells are mediating
part of the effects we have observed by recruiting these effector
populations.
TSP-1 is critical for the mechanism by which host immune
effectors mediate tumor regression upon MYC inactivation.
TSP-1 is a potent cytokine that has been implicated in the regu-
lation of many cellular processes including the regulation of
angiogenesis (Jimenez et al., 2000; Kazerounian et al., 2008;
Lawler, 2000; Short et al., 2005; Zaslavsky et al., 2010). Further-
more, TSP-1 also has been suggested to regulate lymphocyte
homing and function (Li et al., 2006) and appears to be required
for the ability of CD4+ T cells to contribute to sustained regres-
sion upon oncogene inactivation.
Additionally, other cytokines including eotaxin-1, IL-5, IFN-g
and TNF-a are possible candidates for mediating the changes
in cellular senescence and angiogenesis uponMYC inactivation,
consistent with reports that these chemokines may be involved
in these processes (Beatty and Paterson, 2001; Beyne-Rauzy
et al., 2004). The downregulation of other cytokines such as
VEGF, IL-1b, and MCP-1 could also contribute (Kowanetz and
Ferrara, 2006; Shchors et al., 2006; Su et al., 2010). IFN-g and
TNF-a have been previously implicated in the regulation of
cellular quiescence and angiogenesis (Beatty and Paterson,
2001; Beyne-Rauzy et al., 2004; Kuilman et al., 2008; Muller-Her-
melink et al., 2008), and eotaxin-1 and IL-5 have demonstrated
potent antitumor activity in numerous mouse models of cancercer Cell 18, 485–498, November 16, 2010 ª2010 Elsevier Inc. 495
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restoration of p53 expression was also associated with marked
changes in chemokine expression (Xue et al., 2007).
In primary transgenic tumor hosts, an immune compromised
state induced via treatment with cyclosporine A greatly impeded
the consequences of oncogene inactivation. Therefore, our
results generalize in the case when endogenous tumor-host
interactions evolved throughout tumorigenesis. Cyclosporine A
treatment is well known to increase the frequency of hematolog-
ical malignancies in patients (Cockburn and Krupp, 1989; Opelz
and Dohler, 2004). Hence, this agent may impede sensitivity to
oncogene-directed therapies.
An immune intact host was also found to be required for BCR-
ABL inactivation to induce sustained tumor regression in B-ALL.
Similar to MYC inactivation, inactivation of the BCR-ABL onco-
gene resulted in the induction of cellular senescence, the shut-
down of tumor angiogenesis, and ultimately sustained tumor
regression only in the presence of the host immune system.
However, different fromMYC inactivation,BCR-ABL inactivation
appeared to be less capable of suppressing cellular proliferation.
Hence, the host immune system appears to be generally impor-
tant in mediating the consequences of oncogene inactivation.
Thus, oncogene addiction is a consequence of both cell
autonomous processes such as proliferative arrest and
apoptosis as well as host-immune-dependent mechanisms
such as cellular senescence and angiogenesis (Figure 8C).
Upon oncogene inactivation, tumor cells are eliminated primarily
in a cell autonomous manner. However, the kinetics of tumor cell
elimination and the extent of tumor elimination, or minimal
residual disease, as well as the durability of sustained tumor
regression are all dictated by the presence of an immune system
and appear to be strongly associated with its ability to elicit
cellular senescence and shut down angiogenesis. These
processes may contribute to the constraint of minimal residual
disease (Aguirre-Ghiso, 2007). CD4+ T cells are a critical compo-
nent to this phenomenon and TSP-1 emerges as a possible
cytokine regulating these processes. Other immune effectors
and chemokines/cytokines (including IFN-g, eotaxin-1, IL-5,
TNF-a, and MCP-1) are likely to be involved. Immune cells and
inflammation can be important to the pathogenesis of cancer
throughmany effects on the tumor microenvironment (Coussens
and Werb, 2002; Greten and Karin, 2004; Xue et al., 2007).
In general, the deficiency in CD4+ T cells may render the treat-
ment of tumors in patients less efficacious and impede the
complete elimination of tumor cells. Indeed, AIDS patients
exhibit not only a more than 100-fold increased frequency of
lymphomas often associated with MYC overexpression but are
much less responsive to therapy (Boshoff and Weiss, 2002;
Carbone, 2003). Hence, CD4+ T cells may contribute to the effi-
cacy of therapeutic agents.
Our results suggest that screening methods used to identify
therapies that rely on the in vitro study of cell lines or in vivo
analysis of xenograft models in immune compromised hosts
may underestimate the efficacy of a therapy by failing to faithfully
recapitulate tumor-host interactions (Ronnov-Jessen and Bis-
sell, 2009; Weigelt and Bissell, 2008). Moreover, the active
modulation of CD4+ T cell function may enhance the efficacy
of therapeutics for cancer (Gattinoni et al., 2006; Lake and




The generation and characterization of Tet system transgenic lines for condi-
tional expression of MYC, have been described (Felsher and Bishop, 1999).
CD4/, CD8/, CD4/CD8/, and RAG2/ mice were generously pro-
vided in the FVB/N background by Lisa Coussens (University of California,
San Francisco). TSP-1,2/ mice were generously provided by Ben Barres
(Stanford University). Luciferase+L2G85 mice were generously provided by
Robert Negrin (Stanford University). Tet-o-BCR-ABL mice were generously
provided by Daniel Tenen (Harvard University). Genotyping was performed
by PCR on genomic DNA from tails. All animal experiments were approved
by Stanford’s Administrative Panel on Laboratory Animal Care (APLAC) and
in accordance with institutional and national guidelines.
Tumor Surveillance and Tumorigenicity Assays
Mice that were moribund with tumor were either humanely euthanized or
treated with doxycycline in their drinking water (100 mg/ml) to follow tumor
regression and relapse. Statistical comparison of Kaplan-Meier curves is
based on the log-rank test. Further details can be found in Supplementary
Experiemental Procedures.
Reconstitution of RAG2–/– mice
RAG2/mice were injected intravenously (i.v.) with either (1) 203 106 spleno-
cytes from WT or TSP-1,2/ mice or (2) 4X106 CD4+ or CD8+ T cells isolated
from spleens and lymph nodes of WT mice using magnetically activated cell
sorting (MACS). Eight days post reconstitution, mice were bled from the tail
vein and CD4+ and CD8+ T cell reconstitution was verified using FACS.
In Vivo Bioluminescence Imaging
Mice with tumors were anesthetized with a combination of inhaled isoflorane/
oxygen delivered by the Xenogen XGI-8 5-port Gas Anaesthesia System. The
substrate d-luciferin (150 mg/kg) was injected into the animal’s peritoneal
cavity 10 min before imaging. Animals were then placed into a light-tight
chamber and imaged with an IVIS-200 cooled CCD camera (Xenogen,
Alameda, CA) (Contag et al., 1997). Living Image was used to collect, archive,
and analyze photon fluxes and transform them into pseudocolor images by
using Living Image software (Xenogen). At least five mice per group were
injected with tumors expressing luciferase.
Luminex Cytokine Assay
The concentration of 21 cytokines was measured from tumor tissue lysates
fromWT and RAG2/mice at tumor onset and 4 days afterMYC inactivation.
Concentrations were measured using Luminex xMAP technology. Data were
obtained asmean fluorescence intensity based on a standard curve generated
for each cytokine. Further details can be found in Supplementary Experiemen-
tal Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found online at doi:10.1016/j.ccr.2010.10.002.
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